Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$596.92 USD

596.92
2,138,161

+3.13 (0.53%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM

CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.

BD's (BDX) Latest Buyout to Enhance its Digital Capabilities

BD's (BDX) acquisition of Scanwell is expected to significantly transform its at-home solutions both at present and in the future.

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.

Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.

Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now

Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.

Thermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know

In the latest trading session, Thermo Fisher Scientific (TMO) closed at $651.70, marking a +0.99% move from the previous day.

Here's Why You Should Retain Masimo (MASI) Stock For Now

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.

Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic

Zimmer Biomet (ZBH) continues to face COVID-induced challenges and market pressure.

Cerner's (CERN) Acquisition by Oracle to Boost Patient Outcome

Cerner's (CERN) buyout is likely to aid in growing its community presence as well as improve patient outcomes.

STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment

The latest spin-off of STERIS' (STE) Renal Care business is expected to partly reduce the company's debt burden.

Trina Mukherjee headshot

3 Promising Gene Sequencing Stocks to Watch Out For in 2022

Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.

Here's Why You Should Add LabCorp (LH) to Your Portfolio Now

Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.

Integra (IART) Businesses Rebound Despite Supply Issues

Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.

Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M

Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.

Here's Why You Should Invest in West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business.

Medtronic (MDT) Businesses Rebound Amid Raging Pandemic

Medtronic (MDT) is registering strong organic growth in the Cardiovascular, Neuroscience and Diabetes segments on product launches.

Bruker (BRKR) Introduces JPK NanoWizard V for AFM Research

Bruker's (BRKR) newly-introduced JPK NanoWizard V is expected to significantly contribute to life science atomic force microscopy investigations.

Edwards Lifesciences' (EW) SAPIEN 3 With Alterra Gets FDA Nod

Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.

Here's Why You Should Retain DexCom (DXCM) Stock For Now

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Accuray's (ARAY) CyberKnife System Gets Shonin Approval

Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.

Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?

Here is how Thermo Fisher Scientific (TMO) and West Pharmaceutical Services (WST) have performed compared to their sector so far this year.

Here's Why You Should Hold on to Alcon (ALC) Stock for Now

Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.